GSK's Synflorix and non-typeable H.influenzae - the secret to beating Wyeth? Published 2nd April 2009
The recent EU approval and ongoing development of GSK Biological's new pneumococcal vaccine Synflorix point towards Non-typeable Haemophilus influenzae (NTHi) becoming an increasingly significant target for vaccine development. Within recent research, VacZine Analytics discusses current competitive drivers behind the selection of the pathogen, particularly considerations within acute otitis media (AOM) and pneumonia. Overtime, Wyeth could have a potential weakness.
PREMIUMThis article is available only to individual VacZine Analytics clients or can be purchased for delivery.